SAB Biotherapeutics, Inc. (SABS) — Stock Score Summary

SAB Biotherapeutics, Inc. (SABS) has a MoatMap StockRank of 34/100 based on Quality (45/100), Value (42/100), and Momentum (34/100) factor scores. The current signal is SELL. SAB Biotherapeutics is a micro-cap clinical-stage immunotherapy company that lacks the financial self-sustainability, high ROIC, and established moat required by our quality compounding criteria. It has no clear alignment with our active macro themes.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies based on its proprietary DiversitAb platform, which utilizes transchromosomic cattle to produce fully human polyclonal antibodies. This unique technology provides a distinct competitive moat, enabling the generation of high-affinity antibodies with broad therapeutic potential across infectious diseases, oncology, and autoimmune disorders. As an early-stage biotech, SAB Biotherapeutics represents a high-risk, high-reward investment focused on disruptive antibody-based treatments.

Key Financial Metrics

Price$3.36
Market Cap$273M
P/E (Forward)-3.88
Price/Book1.16
Return on Equity-0.3%
Return on Invested Capital8.3%
Debt/Equity2.72
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-31M

SAB Biotherapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is SAB Biotherapeutics, Inc.’s (SABS) StockRank?
MoatMap’s StockRank for SAB Biotherapeutics, Inc. (SABS) is 34/100, with a Sell signal. It is a composite of Quality (45), Value (42), and Momentum (34) factor ranks across MoatMap’s 19,000+ stock universe.
Does SAB Biotherapeutics, Inc. have an economic moat?
SAB Biotherapeutics, Inc. (SABS) has a Quality factor score of 45/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is SAB Biotherapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for SAB Biotherapeutics, Inc. (SABS) is Sell, based on a StockRank of 34/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is SAB Biotherapeutics, Inc. in?
SAB Biotherapeutics, Inc. (SABS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksSABS deep dive reportAI ChampionsHow we score stocksSense-check another stock